Tag:
Intercell
Latest Headlines
Latest Headlines
Intercell seeks drug-patch partners after stock meltdown
Struggling biotech Intercell isn't giving up on its needless patch system for delivering vaccines. After its vax patch flunked multiple trials last year, the Austria-based firm is on the hunt for new
Novartis not keen on buying Intercell, source says
Novartis might not be the knight in shining armor that some perhaps hoped for at struggling vaccine firm Intercell, which has been open to a buyout after a series of development setbacks during the
In fresh blow, Intercell and Merck dump Ph2/3 vaccine study
Just about two months after Intercell CEO Gerd Zettlmeissl insisted that the decision to halt patient recruitment for a Phase II/III trial of its experimental vaccine V710 did not signal the end of
Intercell pulls Ixiaro batch on potency questions
Austria's Intercell has recalled a batch of its only marketed product, a vaccine against Japanese encephalitis, because of possible potency problems, Reuters reports. The shot, Ixiaro, has been sold
Intercell recalls encephalitis vaccine batch
Austria-based vaccine maker Intercell has recalled a batch of its Japanese encephalitis vaccine Ixiaro in the European Union. The drugmaker says some vaccines at the end of their shelf life lacked
Struggling Intercell replaces its CEO
After stumbling badly in the clinic, Austria's Intercell announced that CEO Gerd Zettlmeissl has abruptly resigned and been replaced by COO Thomas Lingelbach. Late last year shares of Intercell AG,
Intercell shares nosedive as investigators slam brakes on patient recruitment
Austria's Intercell ( $ICLL ) saw its stock take another nasty dive after a safety panel warned investigators against recruiting more patients for a Phase II/III clinical trial of an experimental
Intercell and Novartis collaborate on Pseudomonas vax
Intercell and Novartis are continuing to test an investigational vaccine for Pseudomonas aeruginosa. The disease can cause nosocomial infections that lead to pneumonia and other infections, usually
Intercell readies deep R&D cuts after scrapping vax patch program
Shares of Intercell AG, the last of the independent vaccine makers, cratered after the company announced that it was forced to toss its late-stage vaccine patch project for travelers' diarrhea on the
Intercell scrambles after vax patch flunks PhII
Startled by the unexpected failure of a mid-stage trial of its vaccine adjuvant patch, Intercell AG is changing up the vaccine it used in the study along with the hemagglutinin inhibition assay used
